Thank you for supporting cervical cancer research.​

This is the first large scale clinical trial internationally to assess these screening tests in an HPV vaccinated population.

Primary HPV DNA testing has been reviewed and endorsed as a primary cervical screening method by the International Agency for Research on Cancer.A number of large scale randomised controlled trials of primary HPV DNA screening have found that HPV screening is more sensitive in detecting precancerous lesions than cytology-based screening and that it can safely be conducted at a longer interval (see fig 1). However to date there have been no specific trials that support primary HPV DNA testing for cervical screening in the Australian context.

To learn more about Compass, the new National Cervical Screening Program and gain 40 QI&CPD points, please sign up for an education session

Register your practice

For more information, please contact a VCS Pathology Liaison Physician on 03 9250 0300.

Fig 1. Kaplan-Meier plots of cumulative incidence rate for CIN3+ for women according to baseline test results in first 72 months of follow-up, excluding Denmark and Tübingen.

Dillner J et al. BMJ 2008;337:bmj.a1754 ©2008 by British Medical Journal Publishing Group

Compass in Renewal

Practice Recruitment Pack

Trial information